DDInter248 DDInter915
Bumetanide is a sulfamyl diuretic.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Bumetanide {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Bumetanide {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is associated with {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Bumetanide {u} (Compound) treats {v} (Disease) hypertension
hypertension {u} (Disease) is associated with {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Bumetanide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Bumetanide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Bumetanide {u} (Compound) palliates {v} (Disease) chronic kidney failure
chronic kidney failure {u} (Disease) is associated with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Bumetanide {u} (Compound) downregulates {v} (Gene) COTL1
COTL1 {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Bumetanide (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Indacaterol (Compound)
Bumetanide (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is associated with asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Bumetanide (Compound) treats hypertension (Disease) and hypertension (Disease) is associated with ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Bumetanide (Compound) resembles Indapamide (Compound) and Indapamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Bumetanide (Compound) resembles Indapamide (Compound) and Indapamide (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Bumetanide (Compound) palliates chronic kidney failure (Disease) and chronic kidney failure (Disease) is associated with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Bumetanide (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Indacaterol (Compound)